During an immune response, B cells undergo rapid proliferation and remodeling of immunoglobulin (IG) genes within germinal centers (GCs) to generate memory B and plasma cells. Unfortunately, genotoxic stress associated with the GC reaction also promotes most B cell malignancies. We recently discovered that ATM, activated by AID-dependent DNA double stranded breaks (DSBs) during IG class switch recombination (CSR) in GC B cells, signals through LKB1 to inactivate CRTC2, a known transcriptional co-activator of CREB. Using genome-wide location analysis, we determined that CRTC2 inactivation unexpectedly represses a genetic program that controls GC B cell proliferation, self-renewal, and differentiation into antibody (Ab)-secreting plasma cells while opposing lymphomagenesis. Defects in this pathway were identified in pilot studies of human B cell lymphoma samples by ATM or LKB1 repression or by a recently identified somatic mutation or genetic polymorphism in CRTC2. These pathway alterations are predicted to result in increased GC B cell proliferation and impaired plasma cell differentiation, which will be tested here in vitro and in vivo. Our data show a new outcome for the DNA damage response (DDR) using B lymphocytes as the model system. It is known that DNA damage activates a cellular DDR, which determines 3 main cell fates: 1) transient cell cycle arrest with DNA repair and cycle reentry, 2) permanent exit from the cell cycle (senescence), or 3) apoptosis. Here, we propose to define key molecular determinants and the significance of an unexpected fourth outcome for DNA damage, which is to drive precursor cell maturation, in this case from a GC B cell to an Ab-secreting plasma cell. In a sense, this new outcome is a form of cell senescence, in that a cell with potentially tumorigenic DNA damage is forced out of a rapidly dividing precursor pool to protect the host from cancer. However, this fourth DDR option differs significantly from senescence by coupling with differentiation, which leads to an essential new function, Ab production against infectious agents. The pathway we identified is DSB-initiated ATM->LKB1->"X"->"Y"/CRTC2->target gene expression that controls the transition from a GC B cell to a plasma cell.
In Aim 1, we will identify ~85 kDa LKB1 direct target phosphoprotein "X" by candidate elimination from the 14 member AMPK family and/or by biochemistry- mass spectrometry analysis, followed by shRNA and over-expression studies in a unique human GC B cell differentiation system.
In Aim 2, we will identify CREB-independent CRTC2-interacting "Y" factor(s) that control a gene program that mediates DSB-induced differentiation into plasma cells. These two identification and function aims are essential to complete this novel signaling pathway and to link with Aim 3 studies.
In Aim 3, we provide pre-clinical and clinical relevance by analysis of a unique LKB1 B-lineage knockout (KO) mouse and we determine whether pathway defects in human GC B cell lymphomas result from inherited or somatic alterations. Overall, we dissect a new and unexpected fourth outcome for DNA damage- cell differentiation.

Public Health Relevance

DNA damage is a known driver of cancerous transformation and progression in all cell types. Three defense mechanisms against DNA damage are well known and include 1) temporary cell cycle arrest and accurate DNA repair, 2) permanent exit from cell replication (senescence), or 3) programmed cell death (apoptosis). Recently we identified a novel, fourth option in antibody producing B lymphocytes in which DNA damage drives terminal cell differentiation. Our current proposal seeks to establish key mechanistic and molecular determinants of this fourth outcome to improve our understanding of natural anti-cancer mechanisms and to provide fresh insight for differentiation-driven therapeutic approaches.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA156674-04
Application #
8633428
Study Section
Cellular and Molecular Immunology - B Study Section (CMIB)
Program Officer
Pelroy, Richard
Project Start
2011-04-01
Project End
2016-03-31
Budget Start
2014-05-06
Budget End
2015-03-31
Support Year
4
Fiscal Year
2014
Total Cost
$305,437
Indirect Cost
$104,162
Name
University of California Los Angeles
Department
Pathology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
TeSlaa, Tara; Setoguchi, Kiyoko; Teitell, Michael A (2016) Mitochondria in human pluripotent stem cell apoptosis. Semin Cell Dev Biol 52:76-83
Setoguchi, Kiyoko; TeSlaa, Tara; Koehler, Carla M et al. (2016) P53 Regulates Rapid Apoptosis in Human Pluripotent Stem Cells. J Mol Biol 428:1465-75
TeSlaa, Tara; Chaikovsky, Andrea C; Lipchina, Inna et al. (2016) α-Ketoglutarate Accelerates the Initial Differentiation of Primed Human Pluripotent Stem Cells. Cell Metab 24:485-93
Patananan, Alexander N; Wu, Ting-Hsiang; Chiou, Pei-Yu et al. (2016) Modifying the Mitochondrial Genome. Cell Metab 23:785-96
Wu, Ting-Hsiang; Sagullo, Enrico; Case, Dana et al. (2016) Mitochondrial Transfer by Photothermal Nanoblade Restores Metabolite Profile in Mammalian Cells. Cell Metab 23:921-9
Kim, Diane N H; Teitell, Michael A; Reed, Jason et al. (2015) Hybrid random walk-linear discriminant analysis method for unwrapping quantitative phase microscopy images of biological samples. J Biomed Opt 20:111211
Teslaa, Tara; Teitell, Michael A (2015) Pluripotent stem cell energy metabolism: an update. EMBO J 34:138-53
Teitell, Michael A (2015) Adult stem-like cells exclude "older" mitochondria. Cell Metab 21:658-9
Wang, Geng; Shimada, Eriko; Nili, Mahta et al. (2015) Mitochondria-targeted RNA import. Methods Mol Biol 1264:107-16
Walsh, Nicole C; Waters, Lynnea R; Fowler, Jessica A et al. (2015) LKB1 inhibition of NF-κB in B cells prevents T follicular helper cell differentiation and germinal center formation. EMBO Rep 16:753-68

Showing the most recent 10 out of 43 publications